



## **Follow up to the High-level Group on the Security of Supply of Medical Radioisotopes (HLG-MR)**

**Kevin Charlton**

OECD Nuclear Energy Agency  
Analyst – Division of Nuclear Development

## Forward Plan Beyond 2018

- At the HLG-MR Meeting on 9 October 2018, delegates reconfirmed the recommendation of the activities that should be transferred to the NTE Programme of Work for the 2019-2020 period:
  - continued preparation and publication of the Mo-99 Demand and Capacity Projection report series
  - retain the ability to arrange ad hoc meetings of stakeholders (up to two per year)
  - ability to coordinate communications among the current members of the group should the need arise
  - follow-up work/analysis on the OECD Health Division project


## Demand and Capacity Review 2019-2024

- The 2019 Medical Isotope Supply Review:  $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$  Market Demand and Production Capacity Projection, 2019-2024 - the latest in a series of reports has been reviewed and is now in the publication process:-
  - Positive News
    - the market has converted to >70% non-HEU based supply
    - first alternative technology project licensed (NorthStar RadioGenix)
    - new ANM (Australia) facility recently licensed (June 2019)
  - Negative News
    - NTP (South Africa) problems led to “chronic” shortage situation in most markets during late 2017, during 2018 and in early 2019
    - further project delays and some projects stopped due to economics
    - processing capacity is likely to be tight until at least 2021


## 2019 Demand and Capacity Report - Table 4 new processors

Processor	Targets <sup>5</sup>	Anticipated Mo-99 production weeks/year	Expected available capacity per week (6-day Ci) by 2023 <sup>6</sup>	Expected available capacity per year (6-day Ci <sup>99</sup> Mo) by 2023 <sup>6</sup>	Estimated first full year of production	Project status (January 2018)
MURR/NorthStar	Natural Mo target	52	Approved 750	39 000	2019 ↑	FDA approval Feb 2018 ↑
MURR/NorthStar <sup>1</sup>	Enriched Mo target	52	+2 250	+117 000	2021 ↓	In production scale up
NorthStar	Non-fissile	52	3 000	156 000	2022 ↓	Accelerator vendor selected, initiating scale up
			Cancelled			
SHINE	LEU solution	50	Further delayed 4 000	200 000	202?	Construction Permit Granted
CNEA	LEU	48	2 500	120 000	2021	Building start by end 2018
Korea <sup>2</sup>	LEU	43	Further delayed 4 000	17 200	2024+ ↓	Construction permit in review by regulatory body
MARIA: Mo-99 2010 <sup>3</sup>	LEU	40	Further delayed 3 000	12 000	2024+ ↓	Financing – not yet agreed
Brazil MR	LEU	41	Further delayed 1 000	41 400	2024+ ↓	Detailed design still to be contracted. Construction depends on budget
China Advanced RR <sup>4</sup>	LEU	34	Further delayed 4 000	34 000	2024+ ↓	Financing decision after 2017 tests


## 2019-2024 Processing Capacity (Fig. 6.2 Projections)




## 2019-2024 Processing Capacity (Fig. 6.2 Projections)




## 2019-2024 Processing Capacity (Fig. 6.2 Projections)




## 2019-2024 Processing Capacity (Fig. 6.2 Projections)




## 2019-2024 Processing Capacity (Fig. 6.2 Projections)




## The Effect of Multiple Project Delays



## The Effect of Multiple Project Delays



## The Effect of Multiple Project Delays



## Supply Status Summary

- Many technical problems have actually been solved and a range of alternative production technologies demonstrated
  - the first alternative technology is now being used in the US market
- Supply was stabilised as a result of the actions of existing supply chain participants and the co-ordination activities of the Nuclear Medicine Europe organisation (NMeu formally AIPES), but challenges remain
  - supply has been stressed since mid-November 2017 due to an unplanned outages at NTP (South Africa)
    - the NMeu Emergency Response Team convened almost weekly during 2018 and continue to monitor the situation closely
    - still some “chronic” supply shortages in 2019

## Supply Status Summary

- LEU targets (market externality determined by governments)
  - >70% market conversion recently achieved
  - but less efficient, more waste and a higher unit cost
- Self-Assessment: 6-policy principle - slow implementation
  - FCR pricing levels have not yet been achieved
  - paid ORC remains under utilised by the supply chain
  - reimbursement levels remain unchanged in many markets
- The market remains economically unsustainable
  - security of supply risks remain
  - continued risk of project delay or cancellation of new investment

## Ad-hoc “Lite” Meeting

- One day meeting 9 July 2019
  - primarily held in “Open” session.
- Main discussion points
  - supply status
  - 2019 Demand and Capacity Forecast
  - some project updates
  - OECD Health Division report
  - advice from participants to the NEA NDC

## Focus of this presentation

### Outline of draft Health Division / NEA report

- |   |   |   |                            |
|---|---|---|----------------------------|
| 1 | Use of Tc-99m in health care                            | } | Discussed before           |
| 2 | Variations in use of Tc-99m across countries            |   |                            |
| 3 | Health care provider payment for NM diagnostic scans    |   |                            |
| 4 | Supply chain analysis                                   | } | Focus of this presentation |
| 5 | Policy options to increase reliability of Tc-99m supply |   |                            |

➤ *Draft report circulated with HLG-MR on 3 July 2019*

## Policy options

- *Policies need to tackle the issue within the supply chain*

### *Policies to move towards full-cost recovery within the Mo-99/Tc-99m supply chain*

1. Phased and coordinated discontinuation of NRR funding by governments of producing countries
2. Increasing price transparency in the supply chain
3. Direct price regulation in the supply chain
4. Introducing a commodities trading platform for bulk Mo-99
5. Direct funding of Mo-99 production by end-user countries

### *Policies to reduce the reliance on the current Mo-99/Tc-99m supply chain*

6. Increasing use of substitute diagnostic imaging modalities or substitute isotopes
7. Move towards alternative methods to produce Mo-99/Tc-99m

## Forward Plan Beyond 2018

- At the HLG-MR Meeting on 9 October 2018, delegates reconfirmed the recommendation of the activities that should be transferred to the NTE Programme of Work for the 2019-2020 period:
  - continued preparation and publication of the Mo-99 Demand and Capacity Projection report series – in publication process
  - retain the ability to arrange ad hoc meetings of stakeholders (up to two per year) – held 9 July 2019
  - ability to coordinate communications among the current members of the group should the need arise – communication has been essential
  - follow-up work/analysis on the OECD Health Division project – report released for review

## Advice from 9 July 2019 Ad-hoc meeting

- Maintain the activities that transferred to the NTE Programme of Work for the 2019-2020 period:
  - continued preparation and publication of the Mo-99 Demand and Capacity Projection report
  - retain the ability to arrange ad hoc meetings of stakeholders (up to two per year)
  - ability to coordinate communications among the current members of the group should the need arise
  - follow-up work/analysis on the OECD Health Division project

[www.oecd-nea.org](http://www.oecd-nea.org)

**Thank you for your attention**